Bystander Tumoricidal Effect in the Treatment of Experimental Brain Tumors
- 1 December 1994
- journal article
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 35 (6), 1094-1103
- https://doi.org/10.1227/00006123-199412000-00012
Abstract
The retrovirus-mediated transfer of the herpes simplex virus-thymidine kinase (HSV-tk) gene into tumor cells renders them sensitive to the cytocidal effect of the antiviral drug ganciclovir. This method has shown promising results as a treatment for experimental brain tumors. These experiments indicate that a major mechanism for the effectiveness of HSV-tk retroviral gene therapy may be the bystander tumoricidal effect. The bystander effect was hypothesized to explain tumor eradication, given that the efficacy of in vivo gene transfer to tumor cells was less than 100%. We demonstrate, in this report, that the bystander tumoricidal effect is a major contributor to the tumoricidal effect of ganciclovir in cell culture experiments using the mouse K1735 C19 cerebral melanoma line, thereby expanding the observation of the bystander phenomenon to a broader range of tumor types. The bystander effect was studied in vitro by coculturing wild-type C19 melanoma cells with HSV-tk-expressing C19 (C19-STK) cells. A maximal tumoricidal effect was seen when only 1 in 10 tumor cells expressed the HSV-tk gene. This suggests that in effect, 1 tumor cell with the HSV-tk gene, when given ganciclovir, will destroy 10 neighboring or bystander cells. The destruction of bystander cells does not appear to be mediated by a soluble factor(s) released into the media but, rather, requires close cell proximity or cell contact. In addition, HSV-tk-expressing C19 cells can exert an antitumoral effect not only on wild-type C19 cells but also on cells from a variety of different tumor cell lines, including a human glioblastoma multiforme cell line, indicating that the bystander effect is not a cell line-specific phenomenon. Finally, we observed that the bystander tumoricidal effect could be harnessed directly without using retrovirus-producing cells to increase survival in the mouse C19 brain tumor model. The potential implications of our findings in treating human brain tumors are discussed.Keywords
This publication has 10 references indexed in Scilit:
- Detection of Helper Virus in Retrovirus StocksCurrent Protocols in Molecular Biology, 1996
- In VitroEvidence That Metabolic Cooperation Is Responsible for the Bystander Effect Observed with HSVtkRetroviral Gene TherapyHuman Gene Therapy, 1993
- Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumorsJournal of Neurosurgery, 1993
- An experimental model of retrovirus gene therapy for malignant brain tumorsJournal of Neurosurgery, 1993
- In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain TumorsScience, 1992
- Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell lineJournal of Neuroscience Research, 1990
- Construction and use of a safe and efficient amphotropic packaging cell lineVirology, 1988
- Development of in vivo models for studies of brain metastasisInternational Journal of Cancer, 1988
- Glial cells metabolically cooperate: a potential requirement for gene replacement therapy.Proceedings of the National Academy of Sciences, 1985
- In Vitro Cultivation of Human Tumors: Establishment of Cell Lines Derived From a Series of Solid Tumors2JNCI Journal of the National Cancer Institute, 1973